ORCHID PHARMA
Back to Balance Sheet
|
ORCHID PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹165 Cr | ₹222 Cr | ₹442 Cr | ₹519 Cr | ₹1,436 Cr |
What is the latest Total Non-Current Liabilities ratio of ORCHID PHARMA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2023 | ₹165 Cr |
Mar2022 | ₹222 Cr |
Mar2021 | ₹442 Cr |
Mar2020 | ₹519 Cr |
Mar2019 | ₹1,436 Cr |
How is Total Non-Current Liabilities of ORCHID PHARMA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹165 Cr | -25.96 | |
Mar2022 | ₹222 Cr | -49.71 | |
Mar2021 | ₹442 Cr | -14.78 | |
Mar2020 | ₹519 Cr | -63.85 | |
Mar2019 | ₹1,436 Cr | - |
Compare Total Non-Current Liabilities of peers of ORCHID PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
ORCHID PHARMA | ₹5,204.6 Cr | -4.4% | -3.4% | 160.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹356,673.0 Cr | -2.9% | 0% | 59.6% | Stock Analytics | |
CIPLA | ₹119,930.0 Cr | 5.8% | 6.2% | 60.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹109,446.0 Cr | 5% | 8% | 25.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹108,261.0 Cr | -2.6% | 15.3% | 114.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,830.6 Cr | 0.9% | -1.5% | 32.2% | Stock Analytics |
ORCHID PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ORCHID PHARMA | -4.4% |
-3.4% |
160.5% |
SENSEX | 2% |
2.3% |
22.2% |
You may also like the below Video Courses